[go: up one dir, main page]

AR119080A1 - Proteínas multiespecíficas - Google Patents

Proteínas multiespecíficas

Info

Publication number
AR119080A1
AR119080A1 ARP200101567A ARP200101567A AR119080A1 AR 119080 A1 AR119080 A1 AR 119080A1 AR P200101567 A ARP200101567 A AR P200101567A AR P200101567 A ARP200101567 A AR P200101567A AR 119080 A1 AR119080 A1 AR 119080A1
Authority
AR
Argentina
Prior art keywords
domain
specifically binds
ankyrin repeat
ankyrin
serum albumin
Prior art date
Application number
ARP200101567A
Other languages
English (en)
Inventor
Christian Reichen
Alexander Link
Julia Hepp
Victor Levitsky
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of AR119080A1 publication Critical patent/AR119080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

Esta divulgación se refiere a proteínas recombinantes multiespecíficas útiles para el tratamiento de cáncer. Reivindicación 1: Una proteína recombinante que comprende: un primer dominio de repetición de anquirina que se une específicamente a proteína de activación de fibroblastos (FAP), un segundo dominio de repetición de anquirina que se une específicamente a 4-1BB, un tercer dominio de repetición de anquirina que se une específicamente a 4-1BB, un cuarto dominio de repetición de anquirina que se une específicamente a albúmina sérica y un quinto dominio de repetición de anquirina que se une específicamente a albúmina sérica, en la que dichos dominios de repetición de anquirina están dispuestos, desde el extremo N-terminal hasta el extremo C-terminal, según la siguiente fórmula: (dominio de unión a albúmina sérica) - (dominio de unión a FAP) - (dominio de unión a 4-1BB) - (dominio de unión a 4-1BB) - (dominio de unión a albúmina sérica).
ARP200101567A 2019-06-04 2020-06-03 Proteínas multiespecíficas AR119080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962857037P 2019-06-04 2019-06-04

Publications (1)

Publication Number Publication Date
AR119080A1 true AR119080A1 (es) 2021-11-24

Family

ID=71069894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101567A AR119080A1 (es) 2019-06-04 2020-06-03 Proteínas multiespecíficas

Country Status (17)

Country Link
US (2) US20200385488A1 (es)
EP (1) EP3980443A1 (es)
JP (1) JP2022535564A (es)
KR (1) KR20220016945A (es)
CN (1) CN114206943A (es)
AR (1) AR119080A1 (es)
AU (1) AU2020289080A1 (es)
BR (1) BR112021024236A2 (es)
CA (1) CA3139051A1 (es)
CO (1) CO2021017845A2 (es)
IL (1) IL288613A (es)
MX (1) MX2021014286A (es)
PH (1) PH12021553000A1 (es)
SG (1) SG11202112921VA (es)
TW (1) TW202112804A (es)
UY (1) UY38739A (es)
WO (1) WO2020245746A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021116462A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
TW202208404A (zh) 2020-05-06 2022-03-01 瑞士商分子組合公司 新穎錨蛋白重複結合蛋白質及其用途
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
EP4198050A4 (en) 2020-08-11 2024-05-01 Kanaph Therapeutics Inc. FUSION PROTEIN WITH IL-12 AND ANTI-CD20 ANTIBODIES AND USE THEREOF
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
JP2024509904A (ja) * 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
CN115197329A (zh) * 2021-04-13 2022-10-18 晶源生物医药(苏州)有限公司 一种4-1bb激动剂及其制备方法和应用
WO2022219185A1 (en) * 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
US20250051441A1 (en) * 2021-12-23 2025-02-13 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
CA3251570A1 (en) 2022-02-11 2025-07-09 Kanaph Therapeutics Inc. Pharmaceutical composition for the treatment of cancer comprising a fusion protein including IL-12, an anti-FAP antibody, and an anticancer agent
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2023194628A2 (en) * 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024037743A1 (en) * 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
CN103459415B (zh) 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
EP3183269A2 (en) 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
LT3224275T (lt) 2014-11-14 2020-05-25 F. Hoffmann-La Roche Ag Antigeną surišančios molekulės, apimančios tnf šeimos ligando trimerą
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
RU2018116402A (ru) * 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
ES2953516T3 (es) * 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso

Also Published As

Publication number Publication date
CA3139051A1 (en) 2020-12-10
MX2021014286A (es) 2022-01-06
BR112021024236A2 (pt) 2022-04-26
EP3980443A1 (en) 2022-04-13
WO2020245746A1 (en) 2020-12-10
KR20220016945A (ko) 2022-02-10
IL288613A (en) 2022-02-01
SG11202112921VA (en) 2021-12-30
AU2020289080A1 (en) 2021-12-23
US20200385488A1 (en) 2020-12-10
US20240190999A1 (en) 2024-06-13
CO2021017845A2 (es) 2022-01-17
JP2022535564A (ja) 2022-08-09
UY38739A (es) 2020-12-31
CN114206943A (zh) 2022-03-18
PH12021553000A1 (en) 2023-08-23
TW202112804A (zh) 2021-04-01

Similar Documents

Publication Publication Date Title
AR119080A1 (es) Proteínas multiespecíficas
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20100054A1 (es) Inmunoglobulina con dominio variable dual
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
JP2016538240A5 (es)
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
EA200701597A1 (ru) Димерные ингибиторы ингибиторов белков апоптоза (iap)
PE20091004A1 (es) Proteinas de union a antigenos c-fms humanos
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX2009003126A (es) Agente para prevenir/tratar el cancer.
PE20181890A1 (es) Contorsbody - un ligante de diana monocatenario
PH12022551828A1 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
PE20181956A1 (es) Polipeptidos que inhiben cd40l
EA201391005A1 (ru) Слитый белок против злокачественной опухоли

Legal Events

Date Code Title Description
FA Abandonment or withdrawal